Research programme: sialylated immunoglobulins - Momenta Pharmaceuticals

Drug Profile

Research programme: sialylated immunoglobulins - Momenta Pharmaceuticals

Alternative Names: hsIVIg; Hyper-sialylated IVIg; M 254; sFc; Sialylation research program - Momenta; sIVIG; Tetra-Fc-sialylated immunoglobulins - Momenta Pharmaceuticals

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virdante Pharmaceuticals
  • Developer Momenta Pharmaceuticals
  • Class Anti-inflammatories; Immunoglobulins; Recombinant proteins
  • Mechanism of Action C-type lectin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 04 Oct 2018 Momenta Pharmaceuticals plans a phase I/II proof of concept study for M 254 in Idiopathic thrombocytopenic purpura in late 2018 or early 2019
  • 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for research development in Inflammation in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top